ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0439

Impact of a Maturing Fistula or Graft on Dialysis Patient Outcomes

Session Information

  • Dialysis: Vascular Access
    November 08, 2025 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 803 Dialysis: Vascular Access

Authors

  • Liu, Andrea Yu-Ling, The University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • Ryno, Jacob, The University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • Hammes, Mary S., The University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • Skolarus, Ted, The University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • Angelos, Peter, The University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • McGill, Rita L., The University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
Background

Catheter (CVC) access is used by ~80% of patients who initiate hemodialysis (HD), but some of these patients also have a fistula (AVF) or graft (AVG) which is not yet ready for use (CVC-Plus). We evaluated patient survival after day 90 and transplant waitlisting for the CVC-Plus group, compared to patients using AVF/G and CVC-only.

Methods

All adult patients enrolled in the US Renal Data System with first-time, incident HD with primary Medicare between 2014-2017 were considered, if still receiving chronic dialysis on day 90. Propensity-matched samples were constructed to balance the characteristics between patients with each type of initial vascular access, including: age, sex, race, BMI, albumin, hemoglobin, eGFR, kidney diagnosis, pre-dialysis nephrology/dietary care, and comorbid conditions. Patient survival was evaluated with Cox regression. Transplant waitlist appearance was evaluated by logistic regression. CVC-plus was the reference group for all models.

Results

Among 236,775 subjects, 58% had CVC-only, 19% had CVC-Plus, and 23% had AVF/G. Median follow up was 34 (IQR: 14-50) months. Mean age was 69.6 years and 44% were female. There were 160,264 deaths (68%) during the study period. Waitlisting occurred for 15% of AVF/G, 9% of CVC-Plus, and 7% of CVC-only.
Compared to CVC-Plus, CVC-only was associated with increased death (HR: 1.19, 95%CI=1.17-1.21), and AVF/G was associated with decreased death (HR: 0.86, 95%CI=0.84-0.87), p<0.001 for both. Compared to CVC-Plus, the odds of being waitlisted were higher in patients with AVF/AVG (OR: 1.56, (95%CI=1.49-1.62), and lower in patients with CVC-only (OR: 0.84, (95%CI=0.80-0.88), p<0.001 for both.

Conclusion

Initiating HD with an unready AVF/G is associated with better survival and more opportunity for transplant waitlisting, compared to having CVC as sole access – but functioning AVF/G are associated with the best outcomes. These associations are robust to extensive propensity matching. Working diligently to secure vascular access is worthwhile, especially as the need for dialysis approaches..

Funding

  • Other NIH Support

Digital Object Identifier (DOI)